Kv1.5 has been proposed as a promising target for the therapy of AF because it is expressed in the atrium but not the ventricle and its inhibition prolongs the atrial AP but does not influence ventricular repolarization (Decher et al., 2004, 2006). Here, KCNA5 is linked to atrial fibrillation.